- Home
- ORLY vs MRNA Comparison
ORLY vs MRNA Comparison
Compare ORLY & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ORLY | MRNA |
|---|---|---|
| Founded | 1957 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto & Home Supply Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.2B | 61.6B |
| IPO Year | 1996 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ORLY | MRNA |
|---|---|---|
| Price | $90.77 | $218.31 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 29 | 23 |
| Target Price | $106.46 | ★ $138.37 |
| AVG Volume (30 Days) | 5.5M | ★ 17.3M |
| Earning Date | 10-28-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.77 |
| EPS | ★ 1.58 | N/A |
| Revenue | $17,781,992,000.00 | ★ $19,263,000,000.00 |
| Revenue This Year | $8.26 | $8.13 |
| Revenue Next Year | $6.21 | $16.26 |
| P/E Ratio | $55.96 | ★ N/A |
| Revenue Growth | ★ 6.42 | 4.29 |
| 52 Week Low | $82.59 | $22.28 |
| 52 Week High | $102.46 | $254.48 |
Technical Indicators
Market Signals| Indicator | ORLY | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 57.86 | 56.59 |
| Support Level | $90.50 | $45.39 |
| Resistance Level | $93.94 | $254.48 |
| Average True Range (ATR) | 2.08 | 22.69 |
| MACD | 0.07 | -2.84 |
| Stochastic Oscillator | 73.08 | 54.62 |
Price Performance
Historical ComparisonAbout ORLY O'Reilly Automotive Inc.
Founded in 1957, O'Reilly Auto Parts is one of the largest specialty retailers of automotive aftermarket parts, tools, supplies, equipment, and accessories, serving both DIY and professional customers. The company operates nearly 6,600 stores across 48 US states, Puerto Rico, Mexico, and Canada. In fiscal 2025, O'Reilly generated nearly $18 billion in sales, with its dual market strategy yielding a balanced revenue mix, split between retail DIY customers (49%) and professional service orders (49%). The balance of its sales is derived from noncore categories, including wholesale distribution to independent parts distributors, heavy-shop equipment sales, and value-added services.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.